title: Immunotherapy in glioblastoma: emerging options in precision medicine.
abstract: Immunotherapy for glioblastoma (GBM) provides a unique opportunity for targeted therapies for each patient, addressing individual variability in genes, tumor biomarkers and clinical profile. As immunotherapy has the potential to specifically target tumor cells with minimal risk to normal tissue, several immunotherapeutic strategies are currently being evaluated in clinical trials in GBM. With the Precision Medicine Initiative being announced in the President's State of the Union Address in 2016, GBM immunotherapy provides a useful platform for changing the landscape in treating patients with difficult disease.
authors.affiliation: Department of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
authors.forename: Tiffany R
authors.initials: TR
authors.lastname: Hodges
authors.affiliation: Department of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
authors.forename: Sherise D
authors.initials: SD
authors.lastname: Ferguson
authors.affiliation: Department of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
authors.forename: Amy B
authors.initials: AB
authors.lastname: Heimberger
mesh_terms: D001932:Brain Neoplasms / Q000276:immunology / Q000628:therapy*; D005909:Glioblastoma / Q000276:immunology / Q000628:therapy*; D006801:Humans; D007167:Immunotherapy / Q000639:trends*; D057285:Precision Medicine / Q000639:trends*
keywords: glioblastoma; immunotherapy; precision medicine